Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7–33.

• Crossref
• PubMed
Siegel RL, Miller KD, Fuchs HE, Cancer statistics, 2022. CA Cancer J Clin 2022;72:7–33.3502020410.3322/caac.21708)| false
• Search Google Scholar
• Export Citation

Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th ed, Vol. 2. Lyon; France: IARC Press; 2017.

• PubMed
Swerdlow SH, Campo E, Harris NL, , eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th ed, Vol. 2. Lyon; France: IARC Press; 2017.)| false
• Search Google Scholar
• Export Citation

Gustavsson A, Osterman B, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in Hodgkin’s lymphoma. Acta Oncol 2003;42:589–604.

• Crossref
• PubMed
Gustavsson A, Osterman B, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in Hodgkin’s lymphoma. Acta Oncol 2003;42:589–604.1459651710.1080/02841860310013346)| false
• Search Google Scholar
• Export Citation

Girinsky T, Pichenot C, Beaudre A, et al. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin’s disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys 2006;64:218–226.

• PubMed
Girinsky T, Pichenot C, Beaudre A, Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin’s disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys 2006;64:218–226.)| false
• Search Google Scholar
• Export Citation

Nieder C, Schill S, Kneschaurek P, et al. Influence of different treatment techniques on radiation dose to the LAD coronary artery. Radiat Oncol 2007;2:20.

• Crossref
• PubMed
Nieder C, Schill S, Kneschaurek P, Influence of different treatment techniques on radiation dose to the LAD coronary artery. Radiat Oncol 2007;2:20.10.1186/1748-717X-2-20)| false
• Search Google Scholar
• Export Citation

Li J, Dabaja B, Reed V, et al. Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma. Int J Radiat Oncol Biol Phys 2011;81:167–174.

• Crossref
• PubMed
Li J, Dabaja B, Reed V, Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma. Int J Radiat Oncol Biol Phys 2011;81:167–174.2064351810.1016/j.ijrobp.2010.05.007)| false
• Search Google Scholar
• Export Citation

Hoppe BS, Flampouri S, Su Z, et al. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2012;84:449–455.

• Crossref
• PubMed
Hoppe BS, Flampouri S, Su Z, Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2012;84:449–455.10.1016/j.ijrobp.2011.12.03422386373)| false
• Search Google Scholar
• Export Citation

Paumier A, Ghalibafian M, Gilmore J, et al. Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 2012;82:1522–1527.

• Crossref
• PubMed
Paumier A, Ghalibafian M, Gilmore J, Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 2012;82:1522–1527.2170515110.1016/j.ijrobp.2011.05.015)| false
• Search Google Scholar
• Export Citation

Filippi AR, Ragona R, Fusella M, et al. Changes in breast cancer risk associated with different volumes, doses, and techniques in female Hodgkin lymphoma patients treated with supra-diaphragmatic radiation therapy. Pract Radiat Oncol 2013;3:216–222.

• Crossref
• PubMed
Filippi AR, Ragona R, Fusella M, Changes in breast cancer risk associated with different volumes, doses, and techniques in female Hodgkin lymphoma patients treated with supra-diaphragmatic radiation therapy. Pract Radiat Oncol 2013;3:216–222.10.1016/j.prro.2012.12.00624674367)| false
• Search Google Scholar
• Export Citation

Charpentier AM, Conrad T, Sykes J, et al. Active breathing control for patients receiving mediastinal radiation therapy for lymphoma: impact on normal tissue dose. Pract Radiat Oncol 2014;4:174–180.

• Crossref
• PubMed
Charpentier AM, Conrad T, Sykes J, Active breathing control for patients receiving mediastinal radiation therapy for lymphoma: impact on normal tissue dose. Pract Radiat Oncol 2014;4:174–180.2476668410.1016/j.prro.2013.07.015)| false
• Search Google Scholar
• Export Citation

Filippi AR, Ciammella P, Piva C, et al. Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2014;89:370–375.

• Crossref
• PubMed
Filippi AR, Ciammella P, Piva C, Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2014;89:370–375.2461381010.1016/j.ijrobp.2014.01.041)| false
• Search Google Scholar
• Export Citation

Voong KR, McSpadden K, Pinnix CC, et al. Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin’s lymphoma. Radiat Oncol 2014;9:94.

• Crossref
• PubMed
Voong KR, McSpadden K, Pinnix CC, Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin’s lymphoma. Radiat Oncol 2014;9:94.10.1186/1748-717X-9-9424735767)| false
• Search Google Scholar
• Export Citation

Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 2014;89:854–862.

• Crossref
• PubMed
Specht L, Yahalom J, Illidge T, Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 2014;89:854–862.10.1016/j.ijrobp.2013.05.00523790512)| false
• Search Google Scholar
• Export Citation

Dabaja BS, Hoppe BS, Plastaras JP, et al. Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood 2018;132:1635–1646.

• Crossref
• PubMed
Dabaja BS, Hoppe BS, Plastaras JP, Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood 2018;132:1635–1646.3010806610.1182/blood-2018-03-837633)| false
• Search Google Scholar
• Export Citation

Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006;79:270–277.

• Crossref
• PubMed
Girinsky T, van der Maazen R, Specht L, Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006;79:270–277.1679775510.1016/j.radonc.2006.05.015)| false
• Search Google Scholar
• Export Citation

Paumier A, Ghalibafian M, Beaudre A, et al. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2011;80:199–205.

• Crossref
• PubMed
Paumier A, Ghalibafian M, Beaudre A, Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2011;80:199–205.10.1016/j.ijrobp.2010.09.00721481723)| false
• Search Google Scholar
• Export Citation

Hoskin PJ, Díez P, Williams M, et al. Recommendations for the use of radiotherapy in nodal lymphoma. Clin Oncol (R Coll Radiol) 2013;25:49–58.

• Crossref
• PubMed
Hoskin PJ, Díez P, Williams M, Recommendations for the use of radiotherapy in nodal lymphoma. Clin Oncol (R Coll Radiol) 2013;25:49–58.10.1016/j.clon.2012.07.011)| false
• Search Google Scholar
• Export Citation

Grégoire V, Mackie TR. State of the art on dose prescription, reporting and recording in Intensity-Modulated Radiation Therapy (ICRU report No. 83). Cancer Radiother 2011;15:555–559.

• Crossref
• PubMed
Grégoire V, Mackie TR. State of the art on dose prescription, reporting and recording in Intensity-Modulated Radiation Therapy (ICRU report No. 83). Cancer Radiother 2011;15:555–559.10.1016/j.canrad.2011.04.00321802333)| false
• Search Google Scholar
• Export Citation

Berrington de Gonzalez A, Gilbert E, Curtis R, et al. Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship. Int J Radiat Oncol Biol Phys 2013;86:224–233.

• Crossref
• PubMed
Berrington de Gonzalez A, Gilbert E, Curtis R, Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship. Int J Radiat Oncol Biol Phys 2013;86:224–233.2310269510.1016/j.ijrobp.2012.09.001)| false
• Search Google Scholar
• Export Citation

Dracham CB, Shankar A, Madan R. Radiation induced secondary malignancies: a review article. Radiat Oncol J 2018;36:85–94.

• Crossref
• PubMed
Dracham CB, Shankar A, Madan R. Radiation induced secondary malignancies: a review article. Radiat Oncol J 2018;36:85–94.2998302810.3857/roj.2018.00290)| false
• Search Google Scholar
• Export Citation

van Nimwegen FA, Ntentas G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood 2017;129:2257–2265.

• Crossref
• PubMed
van Nimwegen FA, Ntentas G, Darby SC, Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood 2017;129:2257–2265.10.1182/blood-2016-09-74033228143884)| false
• Search Google Scholar
• Export Citation

Wright JL, Yom SS, Awan MJ, et al. Standardizing normal tissue contouring for radiation therapy treatment planning: an ASTRO consensus paper. Pract Radiat Oncol 2019;9:65–72.

• Crossref
• PubMed
Wright JL, Yom SS, Awan MJ, Standardizing normal tissue contouring for radiation therapy treatment planning: an ASTRO consensus paper. Pract Radiat Oncol 2019;9:65–72.3057684310.1016/j.prro.2018.12.003)| false
• Search Google Scholar
• Export Citation

Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37:2768–2801.

• PubMed
Zamorano JL, Lancellotti P, Rodriguez Muñoz D, 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37:2768–2801.)| false
• Search Google Scholar
• Export Citation

Hoppe BS, Bates JE, Mendenhall NP, et al. The meaningless meaning of mean heart dose in mediastinal lymphoma in the modern radiation therapy era. Pract Radiat Oncol 2020;10:e147–154.

• Crossref
• PubMed
Hoppe BS, Bates JE, Mendenhall NP, The meaningless meaning of mean heart dose in mediastinal lymphoma in the modern radiation therapy era. Pract Radiat Oncol 2020;10:e147–154.3158648310.1016/j.prro.2019.09.015)| false
• Search Google Scholar
• Export Citation

Totzeck M, Schuler M, Stuschke M, et al. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol 2019;280:163–175.

• Crossref
• PubMed
Totzeck M, Schuler M, Stuschke M, Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol 2019;280:163–175.10.1016/j.ijcard.2019.01.03830661849)| false
• Search Google Scholar
• Export Citation

Maraldo MV, Giusti F, Vogelius IR, et al. Cardiovascular disease after treatment for Hodgkin’s lymphoma: an analysis of nine collaborative EORTC-LYSA trials. Lancet Haematol 2015;2:e492–502.

• Crossref
• PubMed
Maraldo MV, Giusti F, Vogelius IR, Cardiovascular disease after treatment for Hodgkin’s lymphoma: an analysis of nine collaborative EORTC-LYSA trials. Lancet Haematol 2015;2:e492–502.10.1016/S2352-3026(15)00153-226686259)| false
• Search Google Scholar
• Export Citation

van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol 2016;34:235–243.

• Crossref
• PubMed
van Nimwegen FA, Schaapveld M, Cutter DJ, Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol 2016;34:235–243.2657307510.1200/JCO.2015.63.4444)| false
• Search Google Scholar
• Export Citation

Schellong G, Riepenhausen M, Bruch C, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer 2010;55:1145–1152.

• Crossref
• PubMed
Schellong G, Riepenhausen M, Bruch C, Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer 2010;55:1145–1152.2073440010.1002/pbc.22664)| false
• Search Google Scholar
• Export Citation

Cutter DJ, Schaapveld M, Darby SC, et al. Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst 2015;107:107.

• Crossref
• PubMed
Cutter DJ, Schaapveld M, Darby SC, Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst 2015;107:107.10.1093/jnci/djv008)| false
• Search Google Scholar
• Export Citation

Moignier A, Broggio D, Derreumaux S, et al. Coronary stenosis risk analysis following Hodgkin lymphoma radiotherapy: a study based on patient specific artery segments dose calculation. Radiother Oncol 2015;117:467–472.

• Crossref
• PubMed
Moignier A, Broggio D, Derreumaux S, Coronary stenosis risk analysis following Hodgkin lymphoma radiotherapy: a study based on patient specific artery segments dose calculation. Radiother Oncol 2015;117:467–472.10.1016/j.radonc.2015.07.04326277431)| false
• Search Google Scholar
• Export Citation

Hahn E, Jiang H, Ng A, et al. Late cardiac toxicity after mediastinal radiation therapy for Hodgkin lymphoma: contributions of coronary artery and whole heart dose-volume variables to risk prediction. Int J Radiat Oncol Biol Phys 2017;98:1116–1123.

• Crossref
• PubMed
Hahn E, Jiang H, Ng A, Late cardiac toxicity after mediastinal radiation therapy for Hodgkin lymphoma: contributions of coronary artery and whole heart dose-volume variables to risk prediction. Int J Radiat Oncol Biol Phys 2017;98:1116–1123.2872189510.1016/j.ijrobp.2017.03.026)| false
• Search Google Scholar
• Export Citation

Milgrom SA, Varghese B, Gladish GW, et al. Coronary artery dose-volume parameters predict risk of calcification after radiation therapy. J Cardiovasc Imaging 2019;27:268–279.

• Crossref
• PubMed
Milgrom SA, Varghese B, Gladish GW, Coronary artery dose-volume parameters predict risk of calcification after radiation therapy. J Cardiovasc Imaging 2019;27:268–279.3161439810.4250/jcvi.2019.27.e38)| false
• Search Google Scholar
• Export Citation

Atkins KM, Chaunzwa TL, Lamba N, et al. Association of left anterior descending coronary artery radiation dose with major adverse cardiac events and mortality in patients with non-small cell lung cancer. JAMA Oncol 2021;7:206–219.

• Crossref
• PubMed
Atkins KM, Chaunzwa TL, Lamba N, Association of left anterior descending coronary artery radiation dose with major adverse cardiac events and mortality in patients with non-small cell lung cancer. JAMA Oncol 2021;7:206–219.10.1001/jamaoncol.2020.633233331883)| false
• Search Google Scholar
• Export Citation

Gagliardi G, Constine LS, Moiseenko V, et al. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 2010;76(Suppl):S77–85.

• Crossref
• PubMed
Gagliardi G, Constine LS, Moiseenko V, Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 2010;76(Suppl):S77–85.10.1016/j.ijrobp.2009.04.09320171522)| false
• Search Google Scholar
• Export Citation

Cooper BT, Li X, Shin SM, et al. Preplanning prediction of the left anterior descending artery maximum dose based on patient, dosimetric, and treatment planning parameters. Adv Radiat Oncol 2016;1:373–381.

• Crossref
• PubMed
Cooper BT, Li X, Shin SM, Preplanning prediction of the left anterior descending artery maximum dose based on patient, dosimetric, and treatment planning parameters. Adv Radiat Oncol 2016;1:373–381.2874090810.1016/j.adro.2016.08.001)| false
• Search Google Scholar
• Export Citation

Marks LB, Bentzen SM, Deasy JO, et al. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 2010;76(Suppl):S70–76.

• Crossref
• PubMed
Marks LB, Bentzen SM, Deasy JO, Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 2010;76(Suppl):S70–76.2017152110.1016/j.ijrobp.2009.06.091)| false
• Search Google Scholar
• Export Citation

Pinnix CC, Smith GL, Milgrom S, et al. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2015;92:175–182.

• Crossref
• PubMed
Pinnix CC, Smith GL, Milgrom S, Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2015;92:175–182.10.1016/j.ijrobp.2015.02.01025863764)| false
• Search Google Scholar
• Export Citation

Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478–1484.

• Crossref
• PubMed
Canellos GP, Anderson JR, Propert KJ, Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478–1484.10.1056/NEJM199211193272102)| false
• Search Google Scholar
• Export Citation

Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 2013;31:684–691.

• Crossref
• PubMed
Gordon LI, Hong F, Fisher RI, Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 2013;31:684–691.10.1200/JCO.2012.43.480323182987)| false
• Search Google Scholar
• Export Citation

Merli F, Luminari S, Gobbi PG, et al. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol 2016;34:1175–1181.

• Crossref
• PubMed
Merli F, Luminari S, Gobbi PG, Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol 2016;34:1175–1181.10.1200/JCO.2015.62.481726712220)| false
• Search Google Scholar
• Export Citation

Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med 2011;365:203–212.

• Crossref
• PubMed
Viviani S, Zinzani PL, Rambaldi A, ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med 2011;365:203–212.2177470810.1056/NEJMoa1100340)| false
• Search Google Scholar
• Export Citation

Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med 2016;374:2419–2429.

• Crossref
• PubMed
Johnson P, Federico M, Kirkwood A, Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med 2016;374:2419–2429.10.1056/NEJMoa151009327332902)| false
• Search Google Scholar
• Export Citation

Straus DJ, Długosz-Danecka M, Alekseev S, et al. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood 2020;135:735–742.

• Crossref
• PubMed
Straus DJ, Długosz-Danecka M, Alekseev S, Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood 2020;135:735–742.3194514910.1182/blood.2019003127)| false
• Search Google Scholar
• Export Citation

Straus DJ, Długosz-Danecka M, Connors JM, et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol 2021;8:e410–421.

• Crossref
• PubMed
Straus DJ, Długosz-Danecka M, Connors JM, Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol 2021;8:e410–421.3404868010.1016/S2352-3026(21)00102-2)| false
• Search Google Scholar
• Export Citation

Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 2017;390:2790–2802.

• Crossref
• PubMed
Borchmann P, Goergen H, Kobe C, PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 2017;390:2790–2802.10.1016/S0140-6736(17)32134-7)| false
• Search Google Scholar
• Export Citation

Casasnovas RO, Bouabdallah R, Brice P, et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol 2019;20:202–215.

• Crossref
• PubMed
Casasnovas RO, Bouabdallah R, Brice P, PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol 2019;20:202–215.10.1016/S1470-2045(18)30784-830658935)| false
• Search Google Scholar
• Export Citation

Hutchings M, Radford J, Ansell SM, et al. Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: a prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. Hematol Oncol 2021;39:185–195.

• Crossref
• PubMed
Hutchings M, Radford J, Ansell SM, Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: a prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. Hematol Oncol 2021;39:185–195.3346282210.1002/hon.2838)| false
• Search Google Scholar
• Export Citation

Evens AM, Connors JM, Younes A, et al. Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study [published online June 24, 2021]. Haematologica, doi: 10.3324/haematol.2021.278438

• PubMed
Evens AM, Connors JM, Younes A, Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study [published online June 24, 2021]. Haematologica, doi: 10.3324/haematol.2021.278438)| false
• Search Google Scholar
• Export Citation

Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 1993;341:1051–1054.

• Crossref
• PubMed
Linch DC, Winfield D, Goldstone AH, Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 1993;341:1051–1054.10.1016/0140-6736(93)92411-L8096958)| false
• Search Google Scholar
• Export Citation

Moskowitz CH, Kewalramani T, Nimer SD, et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. Br J Haematol 2004;124:645–652.

• Crossref
• PubMed
Moskowitz CH, Kewalramani T, Nimer SD, Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. Br J Haematol 2004;124:645–652.1487125210.1111/j.1365-2141.2003.04828.x)| false
• Search Google Scholar
• Export Citation

Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002;359:2065–2071.

• Crossref
• PubMed
Schmitz N, Pfistner B, Sextro M, Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002;359:2065–2071.1208675910.1016/S0140-6736(02)08938-9)| false
• Search Google Scholar
• Export Citation

Sirohi B, Cunningham D, Powles R, et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol 2008;19:1312–1319.

• Crossref
• PubMed
Sirohi B, Cunningham D, Powles R, Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol 2008;19:1312–1319.10.1093/annonc/mdn052)| false
• Search Google Scholar
• Export Citation

Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;385:1853–1862.

• Crossref
• PubMed
Moskowitz CH, Nademanee A, Masszi T, Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;385:1853–1862.10.1016/S0140-6736(15)60165-925796459)| false
• Search Google Scholar
• Export Citation

Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol 2007;18:1071–1079.

• Crossref
• PubMed
Bartlett NL, Niedzwiecki D, Johnson JL, Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol 2007;18:1071–1079.10.1093/annonc/mdm09017426059)| false
• Search Google Scholar
• Export Citation

Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica 2007;92:35–41.

• Crossref
• PubMed
Santoro A, Magagnoli M, Spina M, Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica 2007;92:35–41.1722963310.3324/haematol.10661)| false
• Search Google Scholar
• Export Citation

Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 2014;32:3490–3496.

• Crossref
• PubMed
Crump M, Kuruvilla J, Couban S, Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 2014;32:3490–3496.2526774010.1200/JCO.2013.53.9593)| false
• Search Google Scholar
• Export Citation

Gopal AK, Press OW, Shustov AR, et al. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma 2010;51:1523–1529.

• Crossref
• PubMed
Gopal AK, Press OW, Shustov AR, Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma 2010;51:1523–1529.10.3109/10428194.2010.491137)| false
• Search Google Scholar
• Export Citation

Gutierrez A, Rodriguez J, Martinez-Serra J, et al. Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma. OncoTargets Ther 2014;7:2093–2100.

• Crossref
• PubMed
Gutierrez A, Rodriguez J, Martinez-Serra J, Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma. OncoTargets Ther 2014;7:2093–2100.10.2147/OTT.S70264)| false
• Search Google Scholar
• Export Citation

Moskowitz AJ, Hamlin PA Jr, Perales MA, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013;31:456–460.

• Crossref
• PubMed
Moskowitz AJ, Hamlin PA Jr, Perales MA, Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013;31:456–460.10.1200/JCO.2012.45.330823248254)| false
• Search Google Scholar
• Export Citation

Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118:5119–5125.

• Crossref
• PubMed
Fehniger TA, Larson S, Trinkaus K, A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118:5119–5125.10.1182/blood-2011-07-362475)| false
• Search Google Scholar
• Export Citation

Johnston PB, Inwards DJ, Colgan JP, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010;85:320–324.

• PubMed
Johnston PB, Inwards DJ, Colgan JP, A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010;85:320–324.20229590)| false
• Search Google Scholar
• Export Citation

Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 2015;125:1236–1243.

• Crossref
• PubMed
Gopal AK, Chen R, Smith SE, Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 2015;125:1236–1243.10.1182/blood-2014-08-595801)| false
• Search Google Scholar
• Export Citation

Garcia-Sanz R, Sureda A, Alonso-Alvarez S, et al. Evaluation of the regimen brentuximab vedotin plus ESHAP (BRESHAP) in refractory or relapsed Hodgkin lymphoma patients: preliminary results of a phase I-II trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO) [abstract]. Blood 2015;126:Abstract 582.

• Crossref
• PubMed
Garcia-Sanz R, Sureda A, Alonso-Alvarez S, Evaluation of the regimen brentuximab vedotin plus ESHAP (BRESHAP) in refractory or relapsed Hodgkin lymphoma patients: preliminary results of a phase I-II trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO) [abstract]. Blood 2015;126:Abstract 582.10.1182/blood.V126.23.582.582)| false
• Search Google Scholar
• Export Citation

Moskowitz AJ, Schöder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosfamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol 2015;16:284–292.

• Crossref
• PubMed
Moskowitz AJ, Schöder H, Yahalom J, PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosfamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol 2015;16:284–292.10.1016/S1470-2045(15)70013-625683846)| false
• Search Google Scholar
• Export Citation

LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood 2018;132:40–48.

• Crossref
• PubMed
LaCasce AS, Bociek RG, Sawas A, Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood 2018;132:40–48.10.1182/blood-2017-11-815183)| false
• Search Google Scholar
• Export Citation

O’Connor OA, Lue JK, Sawas A, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin’s lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol 2018;19:257–266.

• Crossref
• PubMed
O’Connor OA, Lue JK, Sawas A, Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin’s lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol 2018;19:257–266.10.1016/S1470-2045(17)30912-929276022)| false
• Search Google Scholar
• Export Citation

Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015;372:311–319.

• Crossref
• PubMed
Ansell SM, Lesokhin AM, Borrello I, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015;372:311–319.10.1056/NEJMoa1411087)| false
• Search Google Scholar
• Export Citation

Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016;17:1283–1294.

• Crossref
• PubMed
Younes A, Santoro A, Shipp M, Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016;17:1283–1294.2745139010.1016/S1470-2045(16)30167-X)| false
• Search Google Scholar
• Export Citation

Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 2018;36:1428–1439.

• Crossref
• PubMed
Armand P, Engert A, Younes A, Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 2018;36:1428–1439.2958454610.1200/JCO.2017.76.0793)| false
• Search Google Scholar
• Export Citation

Moskowitz AJ, Advani RH, Bartlett NL, et al. Brentuximab vedotin and nivolumab for relapsed or refractory classic Hodgkin lymphoma: long-term follow-up results from the single-arm phase 1/2 study [abstract]. Blood 2019;134(Suppl 1):Abstract 238.

• PubMed
Moskowitz AJ, Advani RH, Bartlett NL, Brentuximab vedotin and nivolumab for relapsed or refractory classic Hodgkin lymphoma: long-term follow-up results from the single-arm phase 1/2 study [abstract]. Blood 2019;134(Suppl 1):Abstract 238.)| false
• Search Google Scholar
• Export Citation

Advani RH, Moskowitz AJ, Bartlett NL, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood 2021;138:427–438.

• Crossref
• PubMed
Advani RH, Moskowitz AJ, Bartlett NL, Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood 2021;138:427–438.10.1182/blood.2020009178)| false
• Search Google Scholar
• Export Citation

Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 2016;34:3733–3739.

• Crossref
• PubMed
Armand P, Shipp MA, Ribrag V, Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 2016;34:3733–3739.2735447610.1200/JCO.2016.67.3467)| false
• Search Google Scholar
• Export Citation

Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 2017;35:2125–2132.

• Crossref
• PubMed
Chen R, Zinzani PL, Fanale MA, Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 2017;35:2125–2132.2844111110.1200/JCO.2016.72.1316)| false
• Search Google Scholar
• Export Citation

Kuruvilla J, Ramchandren R, Santoro A, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2021;22:512–524.

• Crossref
• PubMed
Kuruvilla J, Ramchandren R, Santoro A, Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2021;22:512–524.10.1016/S1470-2045(21)00005-X33721562)| false
• Search Google Scholar
• Export Citation

Moskowitz AJ, Shah G, Schöder H, et al. Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. J Clin Oncol 2021;39:3109–3117.

• Crossref
• PubMed
Moskowitz AJ, Shah G, Schöder H, Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. J Clin Oncol 2021;39:3109–3117.10.1200/JCO.21.01056)| false
• Search Google Scholar
• Export Citation